AbbVie (ABBV) Says Upadacitinib Met Primary Endpoint in Phase 2b Study in Atopic Dermatitis
September 7, 2017 8:05 AM
AbbVie (NYSE: ABBV), a global research and development based biopharmaceutical company, today announced positive top-line results from the Phase 2b ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
